Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Prior treatment

• Patients who have long-term use of immunosuppressants after organ transplantation;
• Patients who are currently using immunosuppressive drugs;
• Received Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications within 14 days prior to the first use of the investigational drug;

Other illness

• Renal vein cancer thrombus;
• General poor condition, anesthesia assessment cannot tolerate general anesthesia surgery;
• Have serious cardiovascular and cerebrovascular diseases, uncontrollable hypertension and diabetes;
• Patients with clear infection or fever;
• Patients who have concurrent malignant tumors, are currently undergoing treatment for other benign or malignant tumors, or have a history of other malignant tumors within the past six months;
• Suffering from active or potentially recurrent autoimmune diseases, except for vitiligo, hair loss, psoriasis, or eczema that do not require systemic treatment; Hypothyroidism caused by autoimmune thyroiditis only requires stable doses of hormone replacement therapy; Type I diabetes requiring only a stable dose of insulin replacement therapy.
• Known history of mental illness, drug abuse, alcoholism, or drug use.

Lab values

• Any past or current illness, treatment, or laboratory test abnormalities may confuse the research results, affect the full participation of the subjects in the study, or participation in the study may not be in the best interests of the subjects.

Other

• lymph node metastasis;
• The tumor surrounds the renal artery;
• Diffuse tumor growth, with no clear boundary from normal renal parenchyma;
• Patients with T-cell lymphoma and myeloma;
• Metastatic renal cell carcinoma.
• Perform systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion).
• Simultaneously enrolled in another clinical study, unless it is an observational, non interventional clinical study or a follow-up period of an interventional study.
• Pregnant or lactating women.

• Voluntarily sign a written informed consent form (ICF).
• Age at the time of enrollment is \>= 18 and under 80 years old, with no gender restrictions.
• The physical fitness score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1;
• Expected survival period \>= 3 months.
• Preoperative biopsy pathology confirmed renal clear cell carcinoma or renal cell carcinoma mainly composed of clear cell carcinoma;
• ECOG score 0 or 1;
• The patient is willing to undergo kidney preservation surgery;
• Indications for kidney preservation surgery are available, but limited renal cancer with high difficulty of kidney preservation surgery (stage T1N0M0 or T2N0M0, must meet R.E.N.A.L. score \>= 10);
• At least one measurable lesion (according to mRECIST v1.1 standard) that is suitable for repeated and accurate measurements.
• Good organ function, screening laboratory test results meet the following criteria: (1) Hematology (no blood components or cell growth factors are allowed to support treatment within 2 weeks before starting treatment): a. Absolute neutrophil count (ANC) \>= 1.5 × 10\^9/L (1500/mm\^3); b. Platelet count (PLT) \>= 100 × 10\^9/L (100000/mm\^3); c. Hemoglobin (HB) \>= 90 g/L; (2) Liver: a. Serum total bilirubin (TBIL) \<= 1.5 × ULN; b. Alanine transaminase (ALT) and aspartate transaminase (AST) \<= 2.5 × ULN; For subjects with liver metastases, AST and ALT are \<= 5 × ULN, while serum albumin (ALB) is \>= 28g/L. Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (APTT) are \<= 1.5 × ULN;
• The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study.